(Reuters) -AstraZeneca breached the UK pharmaceutical industry’s code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years and over, the industry self-regulatory body ruled on Friday.
(Reporting by Yamini Kalia in Bengaluru; Editing by Janane Venkatraman)
